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Abstract 
Aim: There is a lack of appropriate commercially available topical corticosteroid 
formulations for use in oral lichen planus (OLP) and oral lichenoid reaction (OLR). Current 
therapy includes crushing a dexamethasone tablet and mixing it with water for use as a 
mouth rinse. This formulation is aesthetically not pleasing and unpleasant to use in the 
mouth as it is a bitter and gritty suspension, resulting in poor compliance. Thus, the present 
study was designed to formulate and pilot an effective, aesthetically pleasing formulation.  
Methods: A single-blinded, crossover trial was designed, with two treatment arms. Patients 
were monitored for seven weeks. Quantitative and qualitative data was assessed using VAS, 
numeric pain scales, TSQM-9, and thematic analysis to determine primary patient reported 
outcomes including satisfaction, compliance, quality of life and symptom relief.  
Results: Nine patients completed the pilot trial. Data analysis revealed the new 
compounded formulation to be superior to existing therapy due to its convenience, positive 
contribution to compliance, patient perceived faster onset of action and improved symptom 
relief.  
Conclusion: Topical dexamethasone is useful in the treatment of OLP. When carefully 
formulated into a compounded mouth rinse, it improves patient outcomes. 
Key Words: Oral Lichen Planus; Oral Lichenoid Reaction; Dexamethasone; Pain; Quality of 
Life 
Introduction 
Oral lichen planus (OLP) and oral lichenoid reaction (OLR) are oral mucosal diseases 
affecting the general population with a reported prevalence between 0.5 and 2.2%.1,2 
Women aged 40 years and older are more frequently affected than men of the same age 
with a ratio of approximately 3:1.3 OLP is a chronic immunologically-mediated disease that 
may present as white reticular striae, white papular or plaque-like lesions, erythema, 
erosions and ulcerated lesions.4 OLR is a term used to denote lichenoid lesions due to a 
systemically administered medication or the local presence of  dental restorative materials.4  
OLP is often accompanied by pain and discomfort that interfere with daily activities such as 





OLP involves an established immune-mediated pathogenesis in which auto-cytotoxic CD8 T-
lymphocytes trigger apoptosis of epithelial cells resulting in inflammation.4,6 Lesions may 
typically occur on the buccal mucosa, tongue and gingivae.7,8 There  have been reports on 
the potential malignant transformation of OLP.5,9–12  
 
Symptomatic OLP is an ongoing issue for clinicians due to the immunologic complexity and 
refractory nature of the disease. Treatment presents as a challenge, often leaving palliation 
as the primary goal of therapy.13 Therapeutic agents currently used for the treatment of OLP 
include corticosteroids, immunomodulators, and retinoids.5,14 Despite the multitude of 
documented interventions, topical corticosteroids such as dexamethasone are considered 
first line therapy and are effective in the management of symptomatic OLP.13 This is due to 
their anti-inflammatory effects and anti-immunologic properties of suppressing T 
lymphocyte function.13 Although corticosteroids can be administered intra-lesionally or 
systemically, topical therapy remains the treatment of choice as it can be applied to lesions 
with minimal systemic absorption and potential for side effects.4,15 Systemic therapy should 
be reserved for severe, widespread OLP and  cases involving other mucocutaneous sites.4,14   
There are few corticosteroid formulations available for oral application as most have been 
developed for the management of external, dermatological conditions and are not designed 
to be used in the mouth.15 Numerous obstacles are faced when administering preparations 
to this area namely the presence of saliva, taste, limited surface area, poor tissue 
penetration, enzymatic degradation, and accidental swallowing leading to unwanted 
systemic absorption.16 This is particularly challenging when treating OLP as there are further 
difficulties to overcome; such as possible systemic absorption of medicament through the 
breach in the oral epithelium especially in ulcerative type, the importance to minimize the 
potential for direct physical irritation, chemical trauma caused by acidic, spicy, or strongly 
flavored substances which may exacerbate symptoms.17,18 Therefore, when considering a 
formulation for use in conditions such as OLP and OLR, excipients with the potential to 
exacerbate symptoms such as flavoring, coloring, and alcohol should be excluded.4 On the 
contrary excipients that are unlikely to exacerbate the condition and overcome obstacles 
faced in drug delivery to the oral mucosa should be investigated. 
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There is evidence6,19 to support the use of mouth rinses in patients with widespread 
symptomatic OLP as lesions are not easily accessible for the placement of creams, 
ointments or gels. As of April 2016, there are no commercially available steroid-containing 
oral rinses in Australia. Those documented20–22 abroad are designed for systemic use and 
contain excipients such as isopropyl alcohol, flavoring, and acidic buffers which may 
exacerbate OLP if used topically.23 Despite the lack of commercially available products, a 
myriad of formulations or modes of delivery for topical corticosteroids are available through 
compounding pharmacies such as pastes, sprays, adhesive bandages, and mouth rinses.24 
 
Compounding pharmacists are therefore able to overcome the need of an appropriate 
therapy for those with OLP. Current OLP therapy at the research site involves the use of 
crushed 0.5 mg dexamethasone tablets (Dexmethsone, Aspen Pharmacare, Australia) mixed 
with water to be used as a mouth rinse. Patients report an improvement in their condition 
when using this therapy however, the bitter taste of dexamethasone and the presence of 
excipients in tablets result in a gritty and unpleasant formulation. Also of concern is the 
difficulty in preparation of the rinse, being inconvenient to prepare in the workplace and 
alike. This could result in compromising the therapeutic dosage and reluctance to continue 
treatment, leading to poor compliance.19 
 
This pilot trial compared the efficacy of the current therapy, self-formulation (crushed 
tablet) dexamethasone rinse (0.5mg dexamethasone tablet crushed, mixed with up to 20 mL 
water, and then used as a rinse) with 2 mL of a compounded mouth rinse of dexamethasone 
(0.5 mg/2 mL) in patients with clinically diagnosed symptomatic OLP, with respect to 
improving the patient outcomes of satisfaction, compliance, quality of life and symptom 
relief. All participants received a total of 0.5 mg of dexamethasone per dose. 
 
Materials and methods 
The research protocol was approved by the Griffith University Human Research Ethics 
Committee (EC00162). Witnessed written consent was obtained from all patients before 
eligibility to participate was granted by JH and the dental nurse on duty. Thorough clinical 
examination, medical and OLP or OLR disease progression histories were documented 
during the initial visit by an oral medicine specialist (RGN). Participants were randomised 
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into two groups using unbiased randomiser software (Research Randomizer V.3.0) by JH to 
determine which therapy they received first. The details of each participant were put into 
concealed envelopes for un-blinding if any adverse event was to occur. All patients were 
clinically and/or histopathologically diagnosed with OLP or OLR requiring treatment at the 
Oral Medicine Clinic, Griffith Health Clinics, Gold Coast, Australia.  
The inclusion criteria were: 
• diagnosis of OLP requiring treatment 
• otherwise healthy, passing medical assessment  
• 18 years of age or older 
Patients on prescribed medication for OLP (those using oral or topical medications for OLP 
such as corticosteroids, immunomodulators, analgesics, anti-inflammatories or mouth 
rinses) were entered into the trial after an ample washout period calculated by the study 
pharmacist. 
Exclusion criteria included:  
• pregnancy, lactation or intended pregnancy 
• prescribed significant medications with potential for drug interactions 
• significant medical conditions 
• highly dependent on medical care 
• currently taking (and unable to cease) medications with documented 
potential to cause OLR 
• allergy to, or experience of adverse effects from topical corticosteroids or 
excipients in either formulation 
The study was a single blinded, cross-over pilot trial. It consisted of a seven week protocol 
where participants were divided into two groups, “A” or “B”. Each participant had three 
weeks of self-formulation rinse as a ‘control’, a one week washout period, and three weeks 
of treatment with the compounded mouth rinse (Figure 1). If any adverse event was 
reported or suspected the clinician (RGN) was un-blinded and the participant referred for 
appropriate care and treatment discontinued. As the study was a preliminary, small-scale 
pilot it was not registered as a full-scale randomized controlled trial and no power 





Participants were instructed to use 2 mL of the dexamethasone 0.5 mg/2 mL compounded 
mouth rinse or one 0.5 mg tablet crushed and mixed with 20 mL of water three times per 
day, for three weeks. All were instructed to rinse and hold the product in their mouths for a 
minimum of 2-3 minutes and then expectorate along with any saliva produced for the 
following minute, and not to swallow. Participants were also advised to avoid consuming 
food, drinks and cleaning their mouth or teeth for 30 minutes after use. 
 
A team of compounding pharmacists provided patients with both dexamethasone tablets 
for crushing and the compounded mouth rinse which contained unionised, micronized, 
dexamethasone, sweetening and thickening agents, and preserved water. Participants were 
directed to store the compounded mouth rinse protected from light, between 2-8°C and a 
28 day expiry was applied.26 The compounded mouth rinse and tablets for the self-
formulation rinse were provided free of charge for the duration of the study. 
 
Clinical Assessment and Analysis 
Participants were evaluated at weeks 0, 3, 4 and 7 during the treatment period. 
Assessments included an objective numerical score for symptoms, a 100 mm Visual 
Analogue Scale (VAS)27; the Treatment Satisfaction Questionnaire for Medication (TSQM-
9)28; comparisons of clinical photographs; and self-assessment via Patient Daily Diary entries 
to record compliance with each dose and comment on Quality of Life (QoL).  
The severity of pain was measured by a VAS; a 0 to 10 horizontally marked line where 0 
represented no pain and 100 represented worst pain experienced. Analysis of data gathered 
from the TSQM-9 questionnaire was utilised to identify common trends. The scoring system 
for the TSQM-9 was ranked using a 5 point scale (1 = very dissatisfied, 2 = not satisfied, 3 = 
neutral, 4 = satisfied, 5 = very satisfied). The assessment of symptom relief, compliance, and 
QoL occurred daily. Participants recorded a numeric value of perceived symptom severity on 
a scale of 1 (best symptom relief) to 10 (no symptom relief), used a tick-box tool to record 
compliance with each dose, and provided comments on their QoL. Compliance was 
calculated using a percentage of total doses taken over 63 days. Due to the small sample 






Nine participants, two men and seven women, with a mean age of 62.3 years (range 27-78 
years) were enrolled in the trial for a period of six months. Recruitment ceased to allow 
appropriate time for data analysis. All nine patients completed the study; however one 
patient (patient 3) did not return his diary. A summary of the characteristics and clinical 
outcomes of the nine patients is presented in Table 1.  
 
When participants used the compounded mouth rinse, their mean compliance with the 
prescribed dose regimen was 90.06% over 21 days and 63 doses, compared to 77.37% when 
using the self-formulation rinse. Analysis of clinical data from the TSQM-9 revealed the 
compounded mouth rinse more favourable than self-formulation rinse with mean 
improvement in convenience of therapy (22.25%); onset of action (8.48%) and attained 
symptom relief (4.18%).  Clinical photographs (Figures 2 and 3) show a reduction in the size 
of ulcerative lesions after compounded rinse therapy. Patient diaries supported these 
objective findings which related to compliance and convenience, onset of action, QoL, and a 
preference for the compounded mouth rinse over the self-formulation rinse. It was shown 
that a therapy convenient for patients to use resulted in improved compliance where 
improved adherence to therapy resulted in better treatment outcomes. Patients reported 
instantaneous cooling and improved relief from the compounded mouth rinse compared to 
the self-formulation rinse. Improving a patient’s QoL is one of the main goals of therapy and 
an indication for effective symptom relief. In one instance a patient was extremely satisfied 
due to being able to consume spicy foods after therapy with the compounded mouth rinse. 
Patient specific comments on factors pertaining to aesthetics were also an emerging theme 
that impacted upon therapy. It was often reported that taste and texture as well as the 
absence of stinging in the mouth while using the compounded formulation made it a 
preferential dosage form compared to the self-formulation mouth rinse.   
 
Safety Analysis 
No patients experienced or reported systemic or topical adverse reactions. All patients 





There are many unique challenges in an oral medicine (oral physician) practice when it 
comes to topical medication delivery in chronic oral diseases. This is primarily due to the 
lack of availability of commercial formulations designed for the oral cavity because of the 
small market size. A compounding pharmacist is able to use their specialized formulation 
knowledge to contribute to the care of oral medicine patients.29,30 Working collaboratively 
with oral medicine clinicians and their patients enables pharmacists to develop formulations 
tailored to individual therapeutic requirements.29,30 This contributes to a holistic approach 
of patient care where common treatment outcomes are desired such as patient satisfaction, 
QoL, symptom relief and increased compliance.31  
Though not designed for oral environment, products made for systemic, cutaneous and 
nasal preparations such as topical dexamethasone in the form of a crushed tablet mouth 
rinse, aerosols, suspensions, and ointments have shown to be clinically effective in the 
treatment of OLP and OLR.32,33 There is extensive documentation of the use of 
dexamethasone in OLP and other mucocutaneous inflammatory conditions.32,33,34 Evidence 
is suggestive of dexamethasone in the form of a mouth rinse can significantly decrease the 
production of locally produced pro-inflammatory cytokines to give satisfactory clinical 
outcomes in OLP.6,19  The use of a mouth rinse as topical therapy for OLP is thought to be 
more beneficial than other forms as it is a more efficient means for targeting larger areas, 
easily applied to posterior areas of the mouth and extensile surfaces, and most importantly 
lowering systemic absorption rates compared with oral ingestion.31,35  
 
An in vivo study has demonstrated the ability of the buccal mucosa to retain a reservoir of 
long acting glucocorticoids such as dexamethasone after topical application36. Other recent 
studies have also demonstrated a reservoir function of the buccal mucosa using in vitro 
models.37,38 It was found that only 1% of dexamethasone is delivered across the mucosa, 
significantly decreasing the potential for systemic absorption after topical application.37,38 
This permeability profile is ideal for the use of dexamethasone in topical treatment of OLP 





Although the percentage improvements shown in Table 1 do not necessarily translate into 
clinically significant improvements, this pilot trial showed that the use of a specialized 
formulation developed by compounding pharmacists may contribute to better clinical 
outcomes for OLP and OLR patients. Participants experienced improvements in satisfaction, 
compliance, QoL and symptom relief from the compounded mouth rinse compared with the 
self-formulation rinse. The cost of the compounded mouth rinse was only slightly more 
expensive than purchasing the tablets to self-formulate, making it a feasible therapeutic 
option. When given the opportunity, participants unanimously selected the compounded 
mouth rinse as their preferred treatment.  
 A mouth rinse containing unionized, micronized, dexamethasone for optimal mucosal 
absorption, minimal excipients that may cause irritation such as alcohol, and inclusion of 
beneficial excipients to increase retention time at the site of action shows promising 
evidence in OLP therapy. Oral Medicine clinicians should therefore be aware of the benefits 
a compounding pharmacist can contribute to patient outcomes.  
 
Due to the small sample size, single-blinding, short duration of intervention and follow-up, 
this pilot study was unable to evaluate long term safety and efficacy. A full-scale, double 
blinded randomized controlled trial with a larger sample size, a longer duration and follow-
up up and multiple sites is necessary to confirm our findings. The use of a dexamethasone 
compounded mouth rinse could be considered as a treatment for those with OLP and OLR.  
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Table 1. Outcome of topical dexamethasone therapies 
    
Crushed Tablet Rinse (CTR) 
 
Compounded Mouth Rinse (CMR) 

































1 56 F A 80.97 5 5 5  80.93 5 5 5 
2 27 F A 23.81 1 3 3  63.39 5 4 4 
3 55 M B - 3 4 4  - 5 4 4 
4 58 F B 95.23 2 3 4  100 5 4 4 
5 68 F A 93.65 3 4 4  100 4 5 4 
6 70 F A 60.3 4 4 4  87.30 5 4 5 
7 76 F A 95.20 5 5 5  98.40 5 5 5 
8 73 F B 79.34 1 3 3  95.24 5 5 4 
9 78 M B 90.47 4 1 2  95.20 5 2 2 
Mean of 
all pts 62.3   
77.37 
(618.97) 3.11 (28) 3.56 (32) 3.78 (34)  90.06 (720.46) 4.89 (44) 4.22 (38) 4.11 (37) 
         ↑12.69% ↑22.25% ↑8.48% ↑4.18% 
 
 
 
